Navigation Links
Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
Date:5/8/2008

onfirm certain safety and efficacy results from a preceding randomized trial of Genasense combined with dacarbazine in patients who have not previously received chemotherapy. AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study.

Genasense in Chronic Lymphocytic Leukemia (CLL): With guidance from the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, the Company is collecting survival and progression data from its completed Phase 3 trial of Genasense plus chemotherapy in patients with relapsed/refractory CLL. Genta has also submitted a proposed confirmatory Phase 3 protocol of Genasense in CLL to the FDA for Special Protocol Assessment (SPA) and to the European Medicines Agency (EMEA) for Scientific Advice.

G4544: A New Oral Drug for Skeletal Diseases

G4544 is the Company's proprietary small molecule that is intended to treat diseases associated with accelerated bone loss. G4544 contains the active ingredient in Ganite(R). Genta has completed a Phase 1 single-dose study of G4544, whose results will be presented at the 2008 ASCO meeting. The Company had a teleconference with FDA's Endocrinology and Metabolism Division that clarified regulatory steps needed to begin more extensive clinical testing. At present, Genta intends to seek approval of G4544 by a 505(b)(2) regulatory pathway, which may shorten development time by allowing use of bioequivalence studies, rather than trials to demonstrate efficacy and safety.

Tesetaxel: A Leading Oral Taxane with Anticancer Activity

Tesetaxel is the latest addition to the Genta oncology portfolio. This agent was developed to avoid serious effects associated with other taxanes (such as paclitaxel [Taxol(R); Bristol Myers Squibb] and docetaxel [Taxotere(R); sanofi aventis]), including severe infusion reactions, peripheral nerve damage, and drug resistance. More than 250 patients have received tesetaxel, and th
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. Genta Incorporated to Present at the BIO CEO & Investor Conference
10. Genta Announces Common Stock Offering of Approximately $3.1 Million
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
(Date:7/30/2014)... Henderson, CA (PRWEB) July 30, 2014 ... hosting presentations of leading Immunologists, Principle Investigators, scientists ... Charles J Malemud, Professor at Case Western ... be delivering his keynote address on “The ... TNF-a in production of matrix metalloproteinase-9”. Arya Biragyn, ...
(Date:7/29/2014)... July 29, 2014 The advanced optical ... brain that are driving a revolution in the neurosciences ... peer-reviewed journal published by SPIE, the international society ... coincides with the launch of the BRAIN Initiative in ... that lay out a vision for and provide examples ...
(Date:7/29/2014)... A team of researchers has created a new ... three-dimensional textures. These surfaces, made by self-assembly of ... properties including controllable mechanical stiffness and strength, ... certain direction. , "We have demonstrated that mechanical ... form complex three-dimensional microstructures, and that we can ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4A new way to make microstructured surfaces 2
... Korea, August 8, 2011Can a flexible LED conformably placed on ... human brain, or rolled upon the blood vessels, diagnose or ... in the near future. The team of Professor Keon ... developed a new concept: a biocompatible, flexible Gallium Nitride (GaN) ...
... (OTCBB: IAGX) announced today that it received an adverse ... its pending dispute with former distributor TriPharma, LLC and ... a private arbitrator and is conducted under the rules ... Diego, California.  The interim award against the Company and ...
... Sept. 19, 2011 Reportlinker.com announces that ... in its catalogue: Established ... http://www.reportlinker.com/p0618133/Established-and-Emerging-Biotech-Clusters.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechnology There ... focused clusters of biotechnology companies and related ...
Cached Biology Technology:Established and Emerging Biotech Clusters 2Established and Emerging Biotech Clusters 3Established and Emerging Biotech Clusters 4Established and Emerging Biotech Clusters 5Established and Emerging Biotech Clusters 6Established and Emerging Biotech Clusters 7Established and Emerging Biotech Clusters 8
(Date:7/30/2014)... as simple as inserting a medicated, disappearing fabric minutes ... have discovered a potentially faster way to deliver a ... method spins the drug into silk-like fibers that quickly ... of the drug than possible with other topical materials ... women a potentially more effective, discreet way to protect ...
(Date:7/30/2014)... out how to create colors, nature had already perfected ... many different hues, for example. Now scientists are tapping ... way to make colored plastics. Their paper on using ... rather than dyes, to produce color appears in ... Asger Mortensen, Anders Kristensen and colleagues point out that ...
(Date:7/30/2014)... University Professor Steven Chown has been awarded the ... for Excellence in Antarctic Research. , SCAR, an ... high quality international scientific research in the Antarctic ... region in the Earth system. The organisation also ... Treaty System, responsible for governing the region. , ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... Mitochondrial diseases disrupt the power generating machinery within cells ... in the lungs or respiratory tract. A new study ... shows that infection with the pneumonia causing bacteria ... a signaling protein that is associated with mitochondrial disease. ...
... Stony Brook, N.Y., July 27, 2009 - Temperature ... amphibians, crustaceans, and lizards live longer at higher latitudes ... week in the Proceedings of the National Academy ... Dr. Stephan Munch and Ph.D. candidate Santiago Salinas, both ...
... Los Angeles, London, New Delhi, Singapore and Washington DC ... special issue of Medical Decision Making , a ... overwhelm hospital resources even with an extremely effective public ... the attack and initiating a response to it. ...
Cached Biology News:Stress signals link pre-existing sickness with susceptibility to bacterial infection 2Warmer environment means shorter lives for cold-blooded animals 2Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 2
... causing shortages in your laboratory or fellow ... cause unwanted distractions, problems and delays. • ... hard work and endeavour! Bring us your ... and market it internationally. We work under ...
... Perhaps sheer in-house demand is causing shortages ... precious antibody. This can cause unwanted distractions, ... Receive royalties for your hard work ... let us build it up,and market it ...
Topoisomerase I...
...
Biology Products: